Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Stock Index Fund ETF (VXUS) vs GeneDx Holdings Corp (WGS) Price & Performance

Vanguard Total International Stock Index Fund ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Vanguard Total International Stock Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Total International Stock Index Fund ETF trades at $87.06, while GeneDx Holdings Corp trades at $81.74 (market cap $2.32B). The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

VXUSWGS
Sector
Sector/ThematicTechnology
52-Week High
$87.21$167.51
52-Week Low
$70.87$34.51
Market Cap
$2.32B
Enterprise Value
$2.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Stock Index Fund ETF

VXUS trades at $87.21, up 1.03% with strong bullish technical signals from moving averages. The ETF offers broad international diversification with over 8,700 non-U.S. stocks, recently delivering 27.82% total returns over the past year according to Seeking Alpha (August 8, 2026). Institutional interest is growing with multiple firms increasing positions, while analysts highlight its valuation discount to U.S. equities.

The outlook remains positive given international diversification benefits and institutional accumulation, though RSI levels suggest potential near-term consolidation. Key risks include global economic volatility and currency fluctuations. Wall Street sentiment leans bullish with Seeking Alpha maintaining a Buy rating, supported by the ETF's low expense ratio and comprehensive market exposure.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.

Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total International Stock Index Fund ETF

VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.

Read more on VXUS

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS